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Inclusion of Gene-Gene and Gene-Environment
Interactions Unlikely to Dramatically Improve
Risk Prediction for Complex Diseases
Hugues Aschard,1,2,* Jinbo Chen,3 Marilyn C. Cornelis,4 Lori B. Chibnik,5 Elizabeth W. Karlson,6
and Peter Kraft1,2,7
Genome-wide association studies have identified hundreds of common genetic variants associated with the risk of multifactorial
diseases. However, their impact on discrimination and risk prediction is limited. It has been suggested that the identification of
gene-gene (G-G) and gene-environment (G-E) interactions would improve disease prediction and facilitate prevention. We conducted
a simulation study to explore the potential improvement in discrimination if G-G and G-E interactions exist and are known.
We used three diseases (breast cancer, type 2 diabetes, and rheumatoid arthritis) as motivating examples. We show that the inclusion
ofG-G andG-E interaction effects in risk-predictionmodels is unlikely to dramatically improve the discrimination ability of thesemodels.Introduction
Genome-wide association studies (GWASs) have dis-
covered hundreds of common genetic variants associated
with multifactorial diseases. These variants can be added
to classical clinical and environmental risk factors for the
improvement of risk-prediction assessment. However, for
most common diseases, the addition of genetic variants
to traditional risk factors has produced onlymodest impro-
vements.1–9 The subsequent genetic-risk profiles generated
are still unlikely to provide sufficient discrimination to
warrant individualized prevention except when the risks
and costs associated with preventive interventions are
low (but not so low that the benefits of intervention
outweigh the costs for every individual).10–12 It has been
suggested that the identification of statistical interaction
between genetic variants (G-G) or interaction between
genetic variants and environmental risk factors (G-E)
would improve the predictive accuracy of risk models
and facilitate prevention.2,12–14
We explored the potential improvement in the dis-
crimination of genetic-risk models for common complex
diseases by using common markers and common expo-
sures after incorporating G-G and G-E interactions. We
considered the scenario in which multiple statistical inter-
actions between common exposures and common risk
markers exist and are known.We also allowed for the possi-
bility that some genetic markers might be involved in G-G
andG-E interactions yet have nomarginal associationwith
disease; hence, they would not have been detected with
the standard one-marker-at-a-time GWAS approach. This
is arguably a best-case scenario because few replicated
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fied to date;15–18 also, after potential interactions are
allowed for, very few novel markers that have undetectable
marginal effect but that show evidence of association have
been identified.19
Because the effectiveness of genetic-risk models will vary
across diseases with different genetic architectures (defined
by the number of associated loci and the distribution of the
effect magnitude across loci), we considered three different
hypothetical architectures motivated by breast cancer
(BRCA, [MIM 114480]), type 2 diabetes (T2D, [MIM
125853]) and rheumatoid arthritis (RA, [MIM 180300]).
We generated a broad range of hypothetical G-G and G-E
interaction effects for each disease and constrained these
models to be consistent with reported marginal effects
for known genetic, clinical, and environmental risk fac-
tors. We then estimated the increase in discrimination
ability of risk models that include the interactions and
compared it to that of models that do not include the
interactions.Material and Methods
Simulation Scheme
We simulated hypothetical models in which the disease status
was defined as a function of the marginal effects of known genetic
and nongenetic risk factors (see Appendix A) and a random
number of two-way G-G and G-E interaction effects. The interac-
tions were defined such that the marginal effects of the known
risk factors reflect the previously reported effect regardless of the
number and the magnitude of the interactions that were simu-
lated. We studied models in which statistical interactions exist
only between the known risk factors as well as models in whichHealth, Boston, MA 02115, USA; 2Department of Epidemiology, Harvard
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statistical interactions exist between the known risk factors
and unknown risk SNPs that have no marginal effect. In each
scenario, we generated 1,000 replicates of 100,000 women for
whom the genotypes of the known SNPs and environmental
risk were simulated independently, and we generated disease
status by assuming a prevalence of 10% for BRCA, 9% for T2D,
and 2% for RA.
The probability of disease given genotypes and exposures (pene-
trance) was generated with a constrained log-linear model:20
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Here, bj and sl are the marginal effects of SNP Gi and exposure
El, respectively; gj,k and gl,m are the interaction effects between
SNPs j and k and between the exposure El and SNP Gm, respec-
tively. Ijk and Ilm represent the presence (when equal to 1) or
absence (when equal to 0) of interaction between Gj and Gk and
between El and Gm, respectively. A is population-average log
penetrance. Gj is the weight for the genetic main effect, Ei is
the weight for the environmental main effect, wj,k, is the
weight of the interaction between SNPs j and k, and wl,m is the
weight of the interaction between exposure El and SNP Gm
(Appendix B). These weights are chosen so that the marginal
effect of SNP j—that is, the difference in the log penetrance
averaged over other genes and exposures between subjects
carrying one versus zero (or two versus one) copies of the minor
allele for SNP j—equals bj and so that the marginal effect of expo-
sure l is sl. In particular, the expected effect of each interaction
term is equal to 0 within strata defined by either of the following
interacting factors:
E

wj;kgj;k jGk
 ¼ Ewj;kgj;k jGj ¼ 0 and Ewl;mgl;m jEl
¼ Ewl;mgl;m jGm ¼ 0:
This model is identical to themodel generated by the commonly
used parameterization
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where Gj* is the count of minor alleles for SNP j and El* is an
indicator variable for whether a subject is exposed (Appendix B).
Moreover, the interaction parameters g*,* in Equations 1 and 2
are equivalent and have the same interpretation. We chose
Equation 1 over Equation 2 because of the equivalence between
the marginal effects and the parameters bj and sl. This allowed
us to easily constrain the simulated models to have locus-specific
marginal effects and exposure marginal effects similar to those
observed empirically. The simulated models cover a wide rangecNRI¼PrðeventjupÞ3PrðupÞPrðeventjdownÞ3PrðdownÞ
PðeventÞ þ
P
The Amof interaction patterns, including classical supermultiplicative
and submultiplicative effects and more exotic models close to
those described by Evans et al.21
We varied the number of pairwise interactions from one to five
G-G and one to five G-E effects. The interaction effects gj,k and gl,m
were sampled from a normal distribution such that jgj< ln(2) with
95% probability. We chose the range of interaction odds ratios to
be consistent with (1) reported G-E interaction odds ratios, which
are mostly smaller than 2.5;22–27(2) the lack of consistently
replicated large G-G and G-E interactions involving common
variants; and (3) the magnitude of the marginal effects seen in
GWASs. Depending on the scenario we considered, the SNPs noted
with subscripts k and m represent either some of the known risk
SNPs or some hypothetical unidentified risk SNPs that have no
marginal effect.
(We recognize that some of the ‘‘environmental’’ risk factors
that we have chosen—e.g. body mass index (BMI) or family
history of disease—are endogenous factors that might themselves
be under genetic influence or correlated with the risk alleles. Our
simulation model assumes that the risk alleles are not correlated
with the environmental risk factors and that any loci influencing
the ‘‘environmental’’ risk factors have no unmediated influence
on disease risk. This would be the case for many exogenous
exposures that are not correlated with genotypes at the disease
susceptibility loci or for loci whose effect is solely mediated
through the endogenous environment, as might be the case for
FTO, BMI, and T2D. We did not explore situations in which
loci influencing the ‘‘environmental’’ risk factors also have an
unmediated influence on disease given that for most complex
diseases, the overlap between currently known risk loci and loci
associated with ‘‘environmental’’ risk factors is small. We stress
that our simulations focus on the best-case scenario in which
the penetrance model is known; in particular, markers that
have no effect on disease risk conditional on the ‘‘environmental’’
exposure are not included in the penetrance model, and all
relevant endogenous exposures are included in the penetrance
model.).
Estimation of Improvement in Risk Prediction
The improvement in discrimination ability was calculated as the
difference in the area under the receiver operating characteristic
curve (AUC), also called the C-statistic, between the model that
includes only the marginal effect of the known risk factors and
the model that includes the main effects of risk factors and the
simulated interaction effects. The improvement in estimation of
absolute risk was assessed by the continuous net reclassification
index (cNRI)28 before and after the addition of the interaction
effects. The cNRI quantifies the proportion of individuals who
have improved absolute-risk estimates (i.e., cases that tend to
have a higher absolute risk and controls that tend to have a smaller
absolute risk), although the cNRI does not consider the magnitude
of the changes in risk estimates. Unlike the net reclassification
index (NRI),29 the cNRI does not require the specification of risk
categories and thus allows for direct comparison across different
diseases. It is defined as follows:rðnoneventjdownÞ3PrðdownÞPrðnoneventjupÞ3PrðupÞ
PðnoneventÞ ;
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Table 1. Expected Discrimination Ability for BRCA, RA, and T2D Based on Reported Estimated Effect of Genetic and Nongenetic Risk
Factors
Disease
AUC (SD) Sensitivity by Specificitya (SD)
Genetic Model Nongenetic Model Combined Model Genetic Model Nongenetic Model Combined Model
BRCA 0.591 (0.008) 0.558 (0.008) 0.616 (0.010) 0.023 (0.005) 0.017 (0.004) 0.033 (0.010)
RAb 0.687 (0.007) 0.571 (0.009) 0.704 (0.008) 0.055 (0.007) 0.014 (0.004) 0.066 (0.009)
T2D 0.623 (0.009) 0.754 (0.007) 0.786 (0.006) 0.030 (0.005) 0.088 (0.007) 0.122 (0.012)
The following abbreviations are used: AUC, area under the receiver operating characteristic curve; SD, standard deviation; BRCA, breast cancer; RA, rheumatoid
arthritis; and T2D, type 2 diabetes.
aFor a specificity threshold of 0.99.
bRA genetic model and combined model include both SNPs and HLA variants.where Pr(event) and Pr(nonevent) are the probabilities of being
a case or a control, respectively, and Pr(down) and Pr(up) are the
probabilities of having lower or higher risk estimates, respectively,
after the addition of interaction effects in themodel. The cNRI and
AUC are independent of disease prevalence, allowing these
measures to be directly compared across diseases.Results
Disease Models and Marginal Risk Prediction
For the BRCA risk model, we included 15 common SNPs
with marginal relative risks (RRs) ranging from 1.07 to
1.28 and risk-allele frequencies ranging from 0.15 to
0.85 (Table S1, available online). Four of the five com-
ponents of the Gail model 30 were added; these were age
at menarche, the number of previous breast biopsies, age
at first child, and the number of first-degree relatives
who have developed BRCA (age < 50 was not taken into
account because we considered a situation in which all
women were older than 50). We modeled the joint
frequencies of these risk factors by using their empirical
distribution in the Nurses’ Health Study (NHS) (see
Material and Methods and Table S2). For T2D, we included
31 SNPs and four clinical risk factors. The marginal allelic
RRs of the SNPs ranged from 1.09 to 1.40, and risk-allele
frequencies were between 0.10 and 0.93 (Table S3). The
clinical risk factors were obesity (BMI R 30), smoking
status, physical activity, and family history of T2D. We
used the NHS to model the joint frequency of these factors
(Table S4). With a RR of 5.1 and a frequency of 0.25,
obesity was the strongest risk factor of T2D. The three
others have RRs between 1.11 and 3.03 and frequencies
between 0.16 and 0.56. The RA model included 31 SNPs
with RRs ranging from 1.02 to 1.75 and risk-allele fre-
quencies ranging from 0.08 to 0.90 (Table S5). Other
than the 31 common GWAS-identified SNPs, we in-
cluded eight HLA-DRB alleles. The largest effect was
for DRB*0401, which has a frequency of 0.09 for a RR
of 3.30, whereas the other variants had either a low
frequency or a low RR. For ease of computation, all HLA
risk alleles were merged into a single variant that had an
average RR of 2.33 for a frequency of 0.24. We included
only two nongenetic risk factors, smoking and breast
feeding, which have RRs equal to 1.69 and 0.79, respec-964 The American Journal of Human Genetics 90, 962–972, June 8, 2tively. The frequencies of these risk factors were also taken
from the NHS (Table S6).
For each disease, we generated 1,000 replicates of
100,000 women and assigned them a disease status on
the basis of the effects described above. To provide
a benchmark for later simulations, we initially assumed
that there were no G-G or G-E interactions. The smallest
discrimination ability as estimated by our simulation was
observed for the BRCA model: the average AUC for the
model that combined genetic and nongenetic factors was
0.616 (standard deviation [SD] ¼ 0.010). Conversely, T2D
had the highest discrimination ability—it had an AUC of
0.786 (SD ¼ 0.006) for the combined model. The AUC
for RAwas 0.704 (SD¼ 0.008) and was driven by its genetic
component, which was proportionally much higher than
that of the two other models. Overall, the AUCs of the
genetic, nongenetic, and combined models obtained by
simulation (Table 1) were in agreement with the AUCs
reported on real data in the literature (see Appendix B).
Increase in Discrimination if G-G andG-E Interactions
Exist between Known Risk Factors
We added between two and ten G-G and G-E interaction
effects to the simulation models so that the final marginal
effects of known genetic risk variants and clinical
and environmental risk factors were equal to their pre-
viously reported effects (see Material and Methods and
Appendix B). We compared the models that included the
simulated interactions with models that included only
the marginal effects (referred to hereafter as ‘‘marginal
models’’) in terms of their ability to discriminate and
appropriately reclassify cases and controls.
The addition of interaction effects to the risk model
improved the performance of genetic-risk-prediction
models, although the improvement as measured by AUC
and cNRI was modest. (Because we simulated a large
cohort, the improvement in model fit was almost always
statistically significant [the median likelihood-ratio
p value z 1023] whether measured by the differences in
the log likelihood or changes in AUC or cNRI. Our focus
is on the magnitude of these differences.) The cNRI
increased linearly with the number (Figure 1) and the
magnitude (Figure 2) of the simulated interactions. The
average cNRI over all simulations was similar across all012
Figure 1. Absolute Increase in AUC and cNRI by the Number of Interactions Simulated
Breast cancer (BRCA), rheumatoid arthritis (RA), and type 2 diabetes (T2D).three disease models: 0.230 (SD ¼ 0.096), 0.210 (SD ¼
0.092), and 0.200 (SD ¼ 0.096) for BRCA, RA, and T2D,
respectively. The contribution of controls to the cNRI
was slightly higher than the contribution of cases. Approx-
imately 54% of cases had higher risk estimates after inter-
actions were incorporated, whereas 56% of controls had
lower estimates. The highest cNRI was observed when
ten interactions were simulated (0.312 [SD ¼ 0.083],
0.305 [SD ¼ 0.085], and 0.286 [SD ¼ 0.074] for BRCA,
RA, and T2D, respectively); the proportions of cases and
controls that had improved risk estimates in this situation
were 57% and 59%, respectively.
The improvement in discrimination ability as measured
by the AUC differed by risk model (Figures 1 and 2). The
average absolute increase in AUC was 2.82% (SD ¼ 1.74),
1.40% (SD ¼ 1.00), and 0.85% (SD ¼ 0.63) for BRCA, RA,
and T2D, respectively. These differences reflect the
increasing difficulty in producing the same absolute
change in AUC as the baseline AUC increases. The increase
in the difference in mean predicted risk between cases and
controls after the addition of interactions was similar for all
three disease models; however, the variance of predicted
values of cases and controls was higher for models with
a higher baseline AUC, resulting in a lower increase in
the AUC of these models.31
We limited themagnitude of the interaction in the simu-
lations presented in Figures 1, 2, and 4 to relatively smallThe Ameffects (0.5 < RRinteraction < 2 with 95% chances) given
that few larger interaction effects involving known risk
factors for complex diseases have been detected by large-
scale studies conducted on humans to date. In Figure S1,
we explore the impact of larger interaction effects (relative
risk up to 10) and a larger number of interactions (up to 20,
including interactions with SNPs that have no marginal
effect). The improvement in AUC increased with in-
creasing interaction effect; the magnitude of this increase
again differed by disease. For example, for 4–20 in-
teractions, the average absolute improvement in AUC for
0.2 < RRinteraction < 5 was equal to 13.79% (SD ¼ 4.64),
8.21% (SD ¼ 3.19), and 5.35% (SD ¼ 2.37) for BRCA, RA,
and T2D, respectively.
Increase in Discrimination if Interactions Exist
between Known Risk Factors and SNPs with No
Marginal Effect
We estimated the improvement when interactions
between known risk factors and SNPs that have no
marginal effect might also exist. We reconducted the
same simulations but replaced the known SNPs with SNPs
that we generated to have risk-allele frequencies in the
interval [0.05, 0.95] and no marginal effect on the diseases
studied. These simulations show similar results to the
previous scenario, but the improvement was, on average,
slightly lower when compared with the model thaterican Journal of Human Genetics 90, 962–972, June 8, 2012 965
Figure 2. Absolute Increase in AUC and cNRI by the Maximum Interaction Effect Simulated
Breast cancer (BRCA), rheumatoid arthritis (RA), and type 2 diabetes (T2D).included interaction between known risk factors only. The
average absolute improvement in AUC was equal to 2.32%
(SD ¼ 1.46), 1.10% (SD ¼ 0.69), and 0.76% (SD ¼ 0.56) for
BRCA, RA, and T2D, respectively; when interactions only
involved known risk SNPs, the average absolute improve-
ment in AUC was 2.82%, 1.40%, and 0.85% for BRCA,
RA, and T2D, respectively.
Number of Interactions versus Size of the Interaction
We further investigated whether model improvement
was more sensitive to the size of the interaction effects
(as measured by the log-interaction RR denoted as g) or
to the number of interactions. We compared two addi-
tional models. In the first, we fixed the number of interac-
tions at ten and limited the size of the interactions (jgj <
ln(1.2) with 95% probability); in the second, we fixed
the number of interactions at two and simulated only
medium-to-strong interactions (ln(1.5) < jgj < ln(2) with
95% probability). The comparison of the increase in AUC
between these two models for each of the diseases when
1,000 series of each model were simulated is presented in
Figure 3. For all models, the magnitude of interaction leads
to a slightly better AUC improvement than does the
number of interactions. As before, the increase in AUC
decreased as the discrimination of the marginal model
increased, and the highest difference was observed for
BRCA. For this model, the absolute increase in AUC was966 The American Journal of Human Genetics 90, 962–972, June 8, 2on average 2.32% (SD ¼ 0.93) for two strong interactions
and 0.63% (SD ¼ 0.30) for ten low interactions. For RA,
the increases for two and ten interactions were, respec-
tively, 1.00% (SD ¼ 0.44) and 0.64% (SD ¼ 0.31); for
T2D, the increases were 0.27% (SD ¼ 0.14) and 0.15%
(SD ¼ 0.08), respectively.
Impact on Public Health and Clinical Utility
Interpreting the AUC and cNRI can be difficult in terms of
public-health impact because they do not consider dif-
ferent benefits and costs associated with true, false-
positive, and negative results.32 Other measures can be
used depending on context.33–35 Here, we consider sensi-
tivity for a fixed specificity threshold, which corresponds
to a single point on the receiver operating characteristic
(ROC) curve. This measure is relevant when a driving
consideration is the control of false-positive test results,
such as in the case of a population-screening program in
which the intervention that follows a positive test for
a rare disease carries substantial risk. The sensitivity
increase due to the inclusion of interactions for different
specificity thresholds is presented in Figure 4. The average
absolute increase in sensitivity (the percentage of cases
above the risk threshold) was below 0.01 for all disease
models at a high level of specificity (R0.99), whereas for
lower specificity thresholds (R0.90), the improvement
was moderate: 0.033 (SD ¼ 0.001), 0.019 (SD ¼ 0.000),012
Figure 3. Comparison of Increase in AUC
between Models that Include a Low Number of
Strong-Interaction Effects with Models that
Include a Large Number of Low-Interaction
Effects
We compared the absolute increase in AUC
between models that include two strong inter-
actions (dashed line) and models that include
ten low interactions (solid line) for BRCA (blue),
RA (green), and T2D (red). Probability density
functions were estimated from 1,000 simulations
for each scenario.and 0.014 (SD ¼ 0.000) for BRCA, RA, and T2D, respec-
tively. This suggests that there might be modest sensitivity
gains for intermediate risk thresholds with higher false-
positive proportions (>10%), but the gains for high risk
thresholds with small false-positive proportions (<1%)
might be low.Discussion
Although multiple biologic interactions among GWAS-
identified risk loci and clinical risk factors are likely to
contribute to the etiology of many common diseases,
this study suggests that the identification of statistical
interactions among these factors might have a modest
impact on risk prediction and discrimination for common
complex diseases. Moreover, the improvement in risk
prediction was estimated in this study in a best-case
scenario in which the true main effect and interactionFigure 4. Absolute Increase in Sensitivity by Maximum Interaction Effect and Spec
Breast cancer (BRCA), rheumatoid arthritis (RA), and type 2 diabetes (T2D).
The American Journal ofeffect are known and are homogeneous
across all individuals (this might not be
the case in practice). The discriminatory
and predictive accuracy of any model
trained in a finite (and perhaps relatively
small) dataset will be diminished as a
result of model-selection uncertainty (e.g.,incorrectly excluding or including true risk factors or inter-
actions) and variability in parameter estimates. Our quan-
titative results are in agreement with the claim made by
Gail2 that G-G interactions might have a low effect on
discrimination accuracy.
The evidence to date suggests that strong pairwise-
interaction effects (e.g., RR > 2) between known risk SNPs
and classical clinical risk factors are unlikely to be common
for complex diseases. For example, three large studies of
interactions among GWAS-identified BRCA markers and
established risk factors failed to find any compelling
evidence for interaction despite having greater than 90%
power for the detection of interaction RR as low as
1.06,15,18,36 and there are few validated interactions among
established genetic or dietary risk factors for T2D.37 We
chose the distribution of the magnitude of simulated inter-
action effects to be consistent with these equivocal results.
The paucity of replicated statistical G-G and G-E interac-
tions from observational studies in humans contrasts withify Threshold
Human Genetics 90, 962–972, June 8, 2012 967
the rich literature on these interactions in experimental
and free-living model organisms.38,39 A number of factors
might contribute to this contrast, and these include (but
are not limited to) low power for the detection of statistical
interactions as a result of the tagging-SNP approach adop-
ted by GWASs and many candidate-gene studies,40 limited
genetic and environmental diversity in the human studies
to date,41,42 or the actual absence of detectable statistical
interactions in many human populations. Our extended
simulations show that the inclusion of many interactions
(>10) with modest to large effects (interaction odds
ratios >2) might meaningfully increase model discrimina-
tion. It remains an open empirical question whether such
interactions exist.
Large pairwise or higher-order interaction effects in-
volving rare causal variants, rare exposures, or rare allelic
combinations of common risk variants might exist but
were outside of the scope of this study. Pharmacogenetics
is one setting in which large interactions have been
observed.43,44 The odds ratio for adverse drug reactions
for some variants can be relatively large (well over 5),
and, considering that the adverse reaction is typically not
present among those who do not receive the drug, the
gene-drug interaction odds ratio can be thought of as
infinite. However, our focus was on risk screening in the
general population, not on tailoring therapy.
Large interactions involving rare exposures or rare alleles
might help identify individualswho are at particularly high
risk, but because they are rare and the prior probability for
particular interactionswill often be low, reliably identifying
them will be difficult. The impact of a strategy that focuses
on high-risk individuals might offer substantial benefits
for those individuals. However, because most cases arise
among the many at lower risk rather than among the few
who are at high risk, the potential impact on the total
burden of disease in the population might be limited.45
There are many measures that can be used for sum-
marizing the clinical and public-health utility of risk-
prediction models.33,46 We used the AUC. Other measures
such as risk-reclassification tables or the NRI can be used;29
however, a recent study by Mihaescu et al. has shown that
these reclassification measures increase as the AUC in-
creases.47 Most reclassification measurements depend on
risk thresholds that place individuals into risk categories;
different thresholds yield different measures and can
change the relative ranking of risk-prediction models.
Consequently, we used the cNRI, which is a threshold-
free reclassification tool. The cNRI simply measures the
proportion of individuals who have better risk estimates
(cases whose predicted risk increases after the inclusion of
interactions and controls whose predicted risk decreases)
without quantifying the magnitude of the change in risk
estimates. Finally, we also considered the increase in sensi-
tivity for high-specificity thresholds, a more interpretable
measure for public-health recommendation. The inclusion
of G-G and G-E interactions did not dramatically improve
any of these measures.968 The American Journal of Human Genetics 90, 962–972, June 8, 2The identification of G-G and G-E interactions remains
of major interest because it can provide important clues
regarding the biological mechanism of many common
complex diseases.48–50 However, indentifying replicable
statistical interactions between common genetic and non-
genetic risk factors is a very challenging task. Such interac-
tions might only modestly improve risk models designed
for use in the general population (such the Gail score
or the Framingham risk score). Whether such modest
improvements are clinically important will depend on
context. Our results suggest that the improvement of
risk-prediction models (as measured by the change in
average sensitivity) with the use of risk factors withmodest
effects primarily depends on the number of risk factors
included in the model; including nonlinear terms gener-
ally provides little improvement. This suggests that identi-
fying new risk loci and new environmental risk factors
might lead to greater improvements in risk modeling
than incorporating interactions among known risk factors.
We note, however, that G-G and G-E interactions can be
leveraged for the identification of new risk loci and new
modifiable environmental risk factors.19,50–54 Finally, we
stress that although G-G and G-E interactions might
have modest impacts on risk prediction, an understanding
of the interplay between genes and the environment can
provide insights into disease etiology; this understanding,
in turn, can lead to improved treatment and prevention
strategies.Appendix A
The BRCA risk model included SNPs that GWASs have
found to be associated with BRCA at highly stringent levels
of statistical significance in populations of European
ancestry and that were confirmed in at least one indepen-
dent set of cases and controls (Table S1). On the basis of the
catalog of published GWASs,55 we identified 12 SNPs that
match these criteria at the time we were conducting this
study. We also considered three additional SNPs that
match similar criteria but that have been identified in
post-GWAS analysis involving multiple independent
populations. We added these 15 SNPs to the model that
we simulated by using their previously reported estimated
marginal effects. We simulated these SNPs by using the
frequencies obtained from the HapMap CEU56 (Utah resi-
dents with northern and Western European ancestry
from the CEPH collection) samples and the reported per-
allele RRs from discovery studies. We combined these
SNPs with the four components of the Gail score for
women older than 50; these components were age at
menarche, age at first child, number of first-degree relatives
with BRCA, and the number of previous breast biopsies
(Table S2). The odd ratios of these risk factors were ex-
tracted from Gail et al.30 The frequencies were taken
from 1,142 control samples from a BRCA case-control
study nested within the NHS.57012
Table A1. Coding for Terms G, E, andw from Equation 1 and Terms
G* and E* from Equation 2
Stratum G* E* G E w Frequency
Noncarrier,
unexposed
0 0 q p qp (1  q)(1  p)
Carrier,
unexposed
1 0 (1  q) p  (1  q)p q(1  p)
Noncarrier,
exposed
0 1 q (1  p) q(1  p) (1  p)q
Carrier,
exposed
1 1 (1  q) (1  p) (1  q)(1  p) qp
Parameters q and p are the minor allele frequency of the SNP G and the
frequency of the exposure E, respectively.The T2D risk model included loci that have been found
to be associated with T2D at highly stringent levels of
statistical significance; these loci were identified or
replicated by the Diabetes Genetics Replication and
Meta-Analysis (DIAGRAM) consortium, a widespread
collaboration that studies populations of European
descent (the most recent report includes 42,542 case
subjects with T2D and 98,912 control subjects). We used
the most significant SNPs of each loci from the DIAGRAM
consortium and the corresponding reported estimated
effects, and we used frequencies extracted from the
HapMap CEU56 (Table S3) samples. We considered four es-
tablished clinical risk factors: obesity (BMI R 25),
smoking status, physical activity, and family history of
T2D (Table S4). Given that no established risk score exists
for T2D, estimated effects of these risk factors were ex-
tracted from the NHS. Their joint frequencies were taken
from control samples in a case-control study of T2D in
the NHS.58
The RA risk model included established risk factors of
seropositive RA. Selected genetic variants include eight
HLA-DRB1 alleles, SNPs newly identified in GWASs, and
SNPs from candidate genes that have been confirmed in
GWASs to be at a genome-wide significance level. The esti-
mated effects were derived from the largest GWASs and a
recent meta-analysis of all published studies59 (Table S5).
We simulated these SNPs by using the HapMap CEU56
frequencies, and we simulated the DRB loci by using
frequencies extracted from a sample of NHS controls.60Table A2. Equivalence between Penetrance Models from Equations 1
Penetrance
Stratum According to Equation 1
Noncarrier, unexposed A  bq  sp þ gqp
Carrier, unexposed A þ b(1  q)  sp  g(1  q)p
Noncarrier, exposed A  bq þ s(1  p)  gq(1  p)
Carrier, exposed A þ b(1  q) þ s(1  p) þ g(1  q)(1
Parameters q and p are the minor allele frequency of the SNP G and the frequen
The AmWe considered two established clinical risk factors—breast
feeding and smoking status (Table S6). The frequencies of
these risk factors were extracted from the NHS case-control
study of RA,61 whereas the estimated effects were extracted
from the discovery studies.62,63Appendix B
To evaluate the relevance of the simulated models, we
estimated, as an example, the discrimination ability of
the marginal model used for BRCA in a real dataset. For
this aim, we used 1,139 BRCA cases and 1,140 controls
from the NHS study.64 All women considered were post-
menopausal and older than 50. The 15 SNPs of interest
were either genotyped as part of the Cancer Genetic
Markers of Susceptibility Study (CGEMS)65 with the
Illumina 550K or imputed with the software MACH66
and the HapMap (rel22) CEU data.56 The four Gail compo-
nents were extracted from the detailed NHS follow-up
questionnaires that have been mailed biennially to the
full NHS cohort for updating exposure information and
any major medical events.
The genetic model including the 15 SNPs yielded
an AUC of 0.597 (standard error of the mean [SEM] ¼
0.012), the nongenetic model including the four Gail
component yielded an AUC of 0.583 (SEM ¼ 012), and
the combined Gail and SNP model shows an increase in
prediction ability and yielded an AUC of 0.629 (SEM ¼
0.012). These results are in agreement with a previous
study that showed similar results for the Gail model and
slightly lower results for the Gail and SNP models when
using a lower number of SNPs (AUC ¼ 0.618 when Gail
and ten SNPs were used in Wacholder et al.;4 AUC ¼
0.594 when Gail and seven SNPs were used in Mealiffe
et al.3). In comparison, our simulated model with the
same estimates yielded an average AUC of 0.558 (SD ¼
0.008), 0.591 (SD ¼ 0.008), and 0.616 (SD ¼ 0.010)
for the Gail model, the genetic model, and the com-
bined model, respectively, when no interaction was
simulated.
We simulated the interaction effects while constraining
the model to have locus-specific and exposure marginal
effects similar to those observed empirically. Rather than
using the popular parameterization that is based onand 2
According to Equation 2
¼ a
¼ a þ b*
¼ a þ s*
 p) ¼ a þ b* þ s* þ g*
cy of the exposure E, respectively.
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counts of minor alleles for SNPs and indicator variables for
exposures and that includes product interaction terms
(Equation 2), we used a coding scheme that ensures
that the SNP and exposure main-effect parameters bj
and sl are equivalent to the desired marginal effects
(Equation 1). We stress, however, that the two parameteri-
zations yield identical models and, moreover, that the
interaction terms g*,* are equivalent.
We illustrate these two parameterizations in the simple
case in which there is one haploid SNP and one binary
exposure. (The results extend naturally to multiple
diploid SNPs and multiple exposures when it is assumed
that the population is in Hardy-Weinberg equilibrium,
the SNPs are unlinked, and there is no correlation
between the SNPs and exposures.) Table A1 presents the
coding for terms G, E, and w from Equation 1 and terms
G* and E* from Equation 2 over the four possible geno-
type-exposure combinations along with each combina-
tion’s frequency derived with the SNP minor allele
frequency q and the exposure frequency p. These codings
ensure that the expectations for E and w are 0 within
genotype strata and that the expectations for G and w
are also 0 within exposure strata. From this and Equation
1, it follows that the difference in average log penetrance
between carriers and noncarriers of the minor allele is
b and that the difference in average log penetrance
between exposed and unexposed subjects is s. The equiv-
alence between the interaction parameter g in both
models can be seen by the solution of the system of
equations described in Table A2. This yields b* ¼ b  gp,
s* ¼ s  gq, and g* ¼ g.
We validated our simulation model by comparing the
estimated marginal effects of the known risk factors while
either simulating or not simulating interactions. As an
indicator of the goodness of fit, the mean of the average
absolute distance between the estimated marginal additive
effects and the true marginal additive effects for the BRCA
model was equal to 0.030 (0.024 and 0.044 for the SNPs
and the four Gail covariates, respectively) when G-G
and G-E interactions between known risk factors were
simulated.Supplemental Data
Supplemental Data include one figure and six tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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